Research Progress on Long Non-coding RNAs and Drug Resistance of Breast Cancer

doi:10.1016/j.clbc.2019.11.001

	Research Progress on Long Non-coding RNAs and Drug Resistance of Breast Cancer
	Zhang, Xiping; Yang, Hongjian
刊名	CLINICAL BREAST CANCER
	2020-08-01
卷号	20
关键词	Breast cancer Drug resistance Epithelial to mesenchymal transitions (EMT) Long non-coding ribonucleic acids (LncRNAs) Molecular mechanisms
ISSN号	1526-8209
DOI	10.1016/j.clbc.2019.11.001
通讯作者	Yang, Hongjian(yhjzlyy@163.com)
英文摘要	Breast cancer, as the foremost cause of women's death in the world, is highly metastatic and mutable. Resistance to drugs for chemotherapies, endocrine therapies, and targeted therapies is an important factor that impacts the prognosis of breast cancer. Long non-coding ribonucleic acids (LncRNAs) are crucial regulators of intracellular gene expressions. Some researchers have suggested that expression level of several types of LncRNAs were closely related to the prognosis of patients with breast cancer. LncRNAs significantly impact biological processes such as drug transport, detoxication, apoptosis, epithelial to mesenchymal transition (EMT), and autophagy by regulating intracellular signaling pathways such as multi-drug resistance gene 1 (MDR1), nuclear factor erythroid 2-related factor 2 (NRF2), phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR), transforming growth factor-beta (TGF-beta), BRCA1/2, and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B). This paper will summarize research progress on correlations between LncRNA and drug resistance of breast cancer. It will particularly expound molecular mechanisms through which LncRNAs regulate drug resistance of breast cancer. It will further discuss the feasibility as molecular markers for forecasting drug resistance of breast cancer and may be becoming new targets for treating breast cancer in the future. (C) 2020 Elsevier Inc. All rights reserved.
资助项目	Foundation for the 1022 First Level of Innovative Talents of Zhejiang Cancer Hospital, China[.2013102202] ; Key Platform Technological Project of Zhejiang Medical Science and Hygiene[.2016ZDB003]
WOS关键词	EPITHELIAL-MESENCHYMAL TRANSITION ; DNA-DAMAGE ; TAMOXIFEN RESISTANCE ; MULTIDRUG-RESISTANCE ; STEM-CELLS ; E-CADHERIN ; GENE ; METASTASIS ; AUTOPHAGY ; INVASION
WOS研究方向	Oncology
语种	英语
出版者	CIG MEDIA GROUP, LP
WOS记录号	WOS:000558628300016
资助机构	Foundation for the 1022 First Level of Innovative Talents of Zhejiang Cancer Hospital, China ; Key Platform Technological Project of Zhejiang Medical Science and Hygiene
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/70813]
专题	中国科学院合肥物质科学研究院
通讯作者	Yang, Hongjian
作者单位	Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Breast Surg, Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China
推荐引用方式 GB/T 7714	Zhang, Xiping,Yang, Hongjian. Research Progress on Long Non-coding RNAs and Drug Resistance of Breast Cancer[J]. CLINICAL BREAST CANCER,2020,20.
APA	Zhang, Xiping,&Yang, Hongjian.(2020).Research Progress on Long Non-coding RNAs and Drug Resistance of Breast Cancer.CLINICAL BREAST CANCER,20.
MLA	Zhang, Xiping,et al."Research Progress on Long Non-coding RNAs and Drug Resistance of Breast Cancer".CLINICAL BREAST CANCER 20(2020).